In addition, BTK inhibitors decreased inflammatory cytokine levels in chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, and graft-versus-host disease [115]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.